Concepedia

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Pasi A. Jänne, Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, Martin J. Edelman, Miguel A. Villalona‐Calero, Robert A. Kratzke,

Journal of Clinical Oncology · 2012 · 249 citations · 34 references

DOI

Abstract

Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced NSCLC. EGFR mutations identify patients most likely to benefit.

References

34

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier · Journal of the American Statistical Association · 1958 · 38.7K citations

, , +21

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Cancer Statistics, 2010

Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.4K citations · Full text

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations